ArticleFrontiers in cellular and infection microbiology2026
Comparative clinical response, safety, and institutional drug use efficiency of intravenous azithromycin versus erythromycin in pediatric
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to compare real-world clinical response, safety, and institutional medication efficiency of intravenous (IV) azithromycin (AZI) versus erythromycin lactobionate (ERY) in hospitalized children with Methods: A retrospective cohort of 1,049 children with PCR- or serology-confirmed MPP was assembled (AZI: Results: Before matching, ordinal response distributions differed modestly ( Conclusions: IV AZI and IV ERY showed comparable overall clinical response in hospitalized pediatric MPP. The age interaction is a response-heterogeneity signal requiring confirmation, not causal proof of efficacy reversal. ERY carried higher odds of mostly mild adverse events, longer duration, and greater institutional macrolide cost burden. These results support future work on resistance-informed, sequence-aware, and child-appropriate formulation stewardship to improve interpretability, safety precision, and institutional antibiotic sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.